seems a good assessment.
AIMHO,
another observation is that the chair, whilst having an extreme talent for finding and securing promising potential therapies, has not to my knowledge:
negotiated any large sell side pharma transactions;
been involved in any successful large pharma deals at all (one small one at vla), despite being involved for decades;
sold a single IMU asset, despite having p2 assets with strong efficacy, and extremely good safety, data.
And has lead multiple massively dilutive CRs (for non-board SHs), after imv alluding to deals coming (years ago now).
People can draft stories all they like, I'll stick with the facts thanks.
Not advice, DYOR, GLTA.
Media Thread, page-12362
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $490.4M | |||
| Open | High | Low | Value | Volume |
| 6.8¢ | 6.9¢ | 6.6¢ | $647.9K | 9.625M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 309078 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 759722 | 11 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.7¢ |
Change
0.000 ( 0.15 %) |
||||
| Open | High | Low | Volume | ||
| 6.8¢ | 6.9¢ | 6.6¢ | 3602017 | ||
| Last updated 15.57pm 31/05/2024 ? | |||||
| IMU (ASX) Chart |